New hope for myeloma: early trial of HDP-101 targets relapsed patients
NCT ID NCT07529782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug, HDP-101, in Chinese patients with multiple myeloma or similar plasma cell disorders. The goal is to find a safe dose and see if the drug can help control the cancer. About 15 adults who have already tried other treatments will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA AND OTHER PLASMA CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Chao-Yang Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100020, China
-
Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, 250012, China
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.